Lilly to trial kinase inhibitors with Immunocore's TCR candidate in melanoma
This article was originally published in Scrip
Executive Summary
Eli Lilly has signed a second collaboration with Immunocore, this time exploring the use of Immunocore's lead T-cell receptor based investigational therapeutic, IMCgp100, in combination with Lilly's galunisertib (LY2157299) and merestinib (LY2801653) for the treatment of melanoma.
You may also be interested in...
Immunocore Expands IO Pact With Genentech To Target MAGE-A Antigens
Genentech and Immunocore will now co-develop the biotech's therapeutic candidate IMC-C103C, an ImmTAC molecule targeting tumors that express melanoma-associated antigen A4.
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.